AKT1 and melanoma: We then identified that AXL is a key upstream effector of AKT pathway-associated resistance to BRAFi in melanoma with wild-type PTEN26, but not in melanoma with PTEN loss or inactivated PTEN26,27, implicating the existence of a different mechanism of BRAFi resistance in melanoma with impaired PTEN.